Eledon Pharmaceuticals Inc

ELDN

Add to Watchlist

3.800USD

-0.150-3.80%

Close 05/15, 16:00（ET）Quotes delayed by 15 min

Eledon Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

104 / 382

Overall Ranking

229 / 4482

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Eledon Pharmaceuticals Inc Highlights

StrengthsRisks

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target within the costimulatory CD40/CD40L cellular pathway. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. Tegoprubart is engineered to potentially both improve safety and provides pharmacokinetic, pharmacodynamic, and dosing advantages. CD40L is primarily expressed on activated CD4+ T cells, platelets, and endothelial cells while the CD40 receptor is constitutively expressed on antigen-presenting cells, such as macrophages and dendritic cells, as well as B cells.

Undervalued

The company’s latest PE is -4.63, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 43.90M shares, decreasing 21.64% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 176.99K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.06.

Analyst Rating

Based on 7 analysts

Buy

Current Rating

8.333

Target Price

+110.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Eledon Pharmaceuticals Inc is 5.85, ranking 307 out of 382 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

5.85

Change

0



Financials

2.04

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

9.42

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.75

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.03

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Eledon Pharmaceuticals Inc is 6.46, ranking 265 out of 382 in the Biotechnology & Medical Research industry. Its current P/E ratio is -4.63, which is -337.50% below the recent high of 11.00 and -1658.33% above the recent low of -81.45.

Score

Industry at a Glance

Previous score

6.46

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 104/382

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Eledon Pharmaceuticals Inc is 8.57, ranking 98 out of 382 in the Biotechnology & Medical Research industry. The average price target is 8.50, with a high of 12.00 and a low of 4.00.

Score

Industry at a Glance

Previous score

8.57

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Eledon Pharmaceuticals Inc is 8.89, ranking 47 out of 382 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 4.24 and the support level at 3.32, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.17

Change

-0.28

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-15

The current institutional shareholding score of Eledon Pharmaceuticals Inc is 5.00, ranking 135 out of 382 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 56.87%, representing a quarter-over-quarter decrease of 8.92%. The largest institutional shareholder is James Simons, holding a total of 24.60K shares, representing 0.03% of shares outstanding, with 84.44% decrease in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BVF Partners L.P.

6.29M

--

BlackRock Institutional Trust Company, N.A.

3.30M

+5.39%

Defilade Capital Management, L.P.

3.29M

--

Ensign Peak Advisors, Inc.

2.46M

+94.87%

Zimmer Partners, LP

2.38M

+30.64%

Sphera Funds Management Ltd.

2.13M

+66.54%

Blue Owl Capital Holdings LP

1.93M

+96.95%

Adar1 Capital Management LLC

1.82M

--

Geode Capital Management, L.L.C.

1.42M

+3.85%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. No risk assessment score is currently available for Eledon Pharmaceuticals Inc. The Biotechnology & Medical Research industry's average is 3.36. The company's beta value is 0.96. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Eledon Pharmaceuticals Inc

ELDN

6.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.48 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.44 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment